Granulomatous Gastritis (TB - Mycobacterium)

1. Comprehensive Executive Overview

Granulomatous gastritis (GG) secondary to Mycobacterium tuberculosis (TB) is a rare but clinically significant manifestation of extra-pulmonary tuberculosis. While the stomach is generally resistant to TB infection due to the high acidity of gastric juices, the presence of pre-existing pathology—such as peptic ulcer disease, gastric carcinoma, or localized ischemia—can create a favorable environment for the bacillus to colonize the gastric mucosa.

Clinically, this condition presents as a chronic inflammation of the stomach wall characterized by the formation of granulomas—aggregates of immune cells (primarily macrophages) attempting to wall off the mycobacterial infection. Because it often mimics gastric adenocarcinoma or Crohn’s disease, it represents a diagnostic challenge for gastroenterologists and pathologists alike. This guide provides an authoritative overview of the condition, categorized under ICD-10 code K29.6_3.

2. Pathophysiology, Etiology, and Risk Factors

The Etiological Agent

The primary causative agent is Mycobacterium tuberculosis. Infection typically occurs via the hematogenous route (spread from a primary pulmonary focus) or through the ingestion of infected sputum (swallowing bacilli from pulmonary TB).

Pathophysiological Mechanism

The pathogenesis follows a specific immunological cascade:
1. Invasion: Bacilli penetrate the gastric mucosal barrier, often aided by pre-existing mucosal damage.
2. Immune Response: The host’s cell-mediated immunity triggers the recruitment of T-lymphocytes and macrophages.
3. Granuloma Formation: In an attempt to contain the mycobacteria, macrophages transform into epithelioid cells, sometimes fusing to form Langhans-type giant cells, resulting in the classic "caseating granuloma."
4. Tissue Destruction: Chronic inflammation leads to wall thickening, ulceration, and potential obstruction of the gastric outlet.

Risk Factors

• Immunocompromised Status: Patients with HIV/AIDS, long-term corticosteroid use, or organ transplant recipients.
• Pre-existing Gastric Pathology: Chronic gastritis, peptic ulcers, or gastric malignancy.
• Malnutrition: Compromised immune function due to protein-energy malnutrition.
• Endemic Regions: Living in or traveling to areas with a high prevalence of tuberculosis.

3. Signs, Symptoms, and Clinical Presentation

Granulomatous gastritis is notoriously non-specific in its presentation, often leading to delayed diagnosis. Patients frequently report symptoms that overlap with common functional dyspepsia or gastric malignancy.

Common Clinical Manifestations:
* Epigastric Pain: Often dull, aching, or burning in nature.
* Early Satiety: Resulting from wall thickening or strictures.
* Weight Loss and Anorexia: Systemic symptoms associated with chronic infection.
* Hematemesis or Melena: Occurring when granulomatous ulceration erodes into gastric blood vessels.
* Gastric Outlet Obstruction (GOO): In advanced cases, inflammation near the pylorus causes persistent vomiting and fluid/electrolyte imbalance.

4. Standard Diagnostic Evaluation & Workup

The diagnostic workup requires a multi-modal approach combining endoscopy, histopathology, and molecular biology.

Endoscopic Evaluation

Upper endoscopy (EGD) is the primary diagnostic tool. Findings may include:
* Hypertrophic gastric folds.
* Deep, irregular, or "punched-out" ulcers.
* Nodular, friable mucosa.
* Pyloric stenosis or deformities.

Histopathology (Gold Standard)

A biopsy is mandatory. Histopathologists look for:
* Caseating Granulomas: The hallmark of TB infection.
* Special Stains: Ziehl-Neelsen or Fite-Faraco staining to identify Acid-Fast Bacilli (AFB).
* Immunohistochemistry: Used to differentiate from Crohn’s disease or sarcoidosis.

Molecular and Microbiological Assays

• PCR (GeneXpert): Rapid detection of M. tuberculosis DNA. This is highly sensitive and specific.
• Mycobacterial Culture: The definitive test. While it takes several weeks, it allows for drug-susceptibility testing.

5. Therapeutic Interventions

The treatment of TB-associated granulomatous gastritis follows the standardized WHO-recommended anti-tubercular therapy (ATT) regimen.

Pharmacotherapy

The standard regimen consists of an initial intensive phase followed by a continuation phase:
1. Intensive Phase (2 Months): Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), and Ethambutol (E).
2. Continuation Phase (4 Months): Isoniazid (H) and Rifampicin (R).

Note: Treatment duration may be extended based on clinical response and the presence of drug-resistant strains.

Surgical Interventions

Surgery is generally reserved for complications, including:
* Refractory Gastric Outlet Obstruction (GOO).
* Perforation of the gastric wall.
* Massive, uncontrollable hemorrhage.
* Inability to definitively rule out gastric malignancy.

Lifestyle and Supportive Care

• Nutritional Support: High-protein, calorie-dense diet to combat weight loss.
• Monitoring: Periodic liver function tests (LFTs) due to the hepatotoxicity of isoniazid and rifampicin.
• Follow-up: Repeat endoscopy to ensure mucosal healing and rule out residual disease.

6. Frequently Asked Questions (FAQ)

1. Is granulomatous gastritis caused by TB contagious?
Generally, gastric TB is a localized infection and is not considered highly contagious unless the patient also has active pulmonary TB with coughing.

2. Can this condition be mistaken for stomach cancer?
Yes. Granulomatous gastritis often presents as a mass-like lesion that can mimic gastric carcinoma on imaging and endoscopy. Biopsy is essential for differentiation.

3. What is the difference between Crohn’s disease and TB-related gastritis?
Both can cause granulomas. However, TB granulomas are typically "caseating" (cheesy necrosis), whereas Crohn’s granulomas are "non-caseating."

4. How long does the treatment take?
The standard course is a minimum of 6 months, though some cases may require longer depending on the severity and drug resistance profile.

5. Are there side effects to the TB medications?
Yes, common side effects include nausea, fatigue, and elevated liver enzymes. Always report jaundice or severe abdominal pain to your physician immediately.

6. Can I eat normally during treatment?
Patients are encouraged to eat frequent, small, nutrient-dense meals. If gastric outlet obstruction is present, a liquid or soft diet may be required initially.

7. Is surgery always necessary?
No. Most patients respond well to pharmacological treatment alone. Surgery is typically only used for complications like obstructions or perforation.

8. How do doctors confirm it is TB and not another infection?
Confirmation involves a combination of histopathology (seeing the granulomas under a microscope) and PCR testing or culture to identify the M. tuberculosis bacteria.

9. Can this condition lead to stomach cancer later?
Chronic inflammation is a risk factor for malignancy. Successful treatment of the TB infection is vital to reduce long-term mucosal damage and inflammation.

10. Do I need to be isolated?
If your pulmonary workup (chest X-ray and sputum tests) is negative for active lung TB, you generally do not require isolation. Your physician will advise based on your specific case.

Disclaimer: This guide is for educational purposes only and does not replace professional medical advice. Always consult with a board-certified Gastroenterologist or Infectious Disease Specialist for diagnosis and management.

Related Clinical Integration

In a modern clinical setting, the management of Granulomatous Gastritis (TB - Mycobacterium) requires a multidisciplinary approach that integrates diagnostic precision with targeted therapeutic interventions. Diagnostic evaluation often necessitates the use of a Gastroscope (GIF-1TQ260 - Therapeutic) / منظار المعدة (GIF-1TQ260 - علاجي) to obtain tissue samples for histopathological confirmation, while the primary pharmacological strategy relies on standardized anti-tubercular regimens, including Rifampicin / ريفامبيسين 600 mg. Because mycobacterial infections can manifest systemically, clinicians must maintain a high index of suspicion for disseminated disease, particularly when evaluating patients with concurrent skeletal involvement, as detailed in our resources on Epidemiology, Pathogenesis, and Surgical Management of Spinal Infections, Comprehensive Diagnosis and Surgical Evaluation of Spinal Infections, Operative Management of Spinal Infections: A Comprehensive Surgical Guide, Operative Management of Spinal Infections: A Comprehensive Surgical Guide, and Musculoskeletal Tuberculosis and Atypical Infections: Operative Management, ensuring that both gastric and musculoskeletal manifestations are addressed through coordinated, evidence-based care.